Brokerages Anticipate Idera Pharmaceuticals Inc (NASDAQ:IDRA) Will Announce Earnings of -$0.33 Per Share

Wall Street brokerages expect that Idera Pharmaceuticals Inc (NASDAQ:IDRA) will report earnings per share (EPS) of ($0.33) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Idera Pharmaceuticals’ earnings. The lowest EPS estimate is ($0.41) and the highest is ($0.21). Idera Pharmaceuticals reported earnings per share of ($0.45) in the same quarter last year, which indicates a positive year over year growth rate of 26.7%. The company is expected to announce its next earnings results on Wednesday, March 4th.

According to Zacks, analysts expect that Idera Pharmaceuticals will report full-year earnings of ($1.48) per share for the current financial year, with EPS estimates ranging from ($1.59) to ($1.28). For the next fiscal year, analysts expect that the business will post earnings of ($1.20) per share, with EPS estimates ranging from ($1.79) to ($0.70). Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for Idera Pharmaceuticals.

Idera Pharmaceuticals (NASDAQ:IDRA) last posted its quarterly earnings results on Wednesday, November 6th. The biotechnology company reported ($0.39) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.46) by $0.07.

A number of brokerages have recently issued reports on IDRA. Zacks Investment Research raised Idera Pharmaceuticals from a “hold” rating to a “buy” rating and set a $2.75 target price on the stock in a research report on Tuesday, November 12th. HC Wainwright reaffirmed a “buy” rating on shares of Idera Pharmaceuticals in a report on Thursday, November 7th. Finally, JMP Securities reiterated a “market outperform” rating and issued a $7.00 price target on shares of Idera Pharmaceuticals in a research report on Thursday, September 5th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. Idera Pharmaceuticals currently has an average rating of “Buy” and a consensus price target of $7.69.

Shares of IDRA traded down $0.06 during trading hours on Thursday, hitting $1.75. 159,400 shares of the company were exchanged, compared to its average volume of 268,460. The company has a market capitalization of $51.10 million, a PE ratio of -0.77 and a beta of 2.20. The firm has a fifty day simple moving average of $2.30 and a 200-day simple moving average of $2.54. Idera Pharmaceuticals has a one year low of $1.67 and a one year high of $7.00.

In other news, major shareholder Invest Corp Pillar sold 100,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 6th. The shares were sold at an average price of $2.50, for a total transaction of $250,000.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. 3.46% of the stock is owned by insiders.

A number of institutional investors have recently bought and sold shares of the stock. Millennium Management LLC grew its position in Idera Pharmaceuticals by 90.8% during the 3rd quarter. Millennium Management LLC now owns 942,136 shares of the biotechnology company’s stock worth $2,722,000 after purchasing an additional 448,442 shares in the last quarter. Natixis boosted its position in Idera Pharmaceuticals by 61.7% during the 2nd quarter. Natixis now owns 743,618 shares of the biotechnology company’s stock worth $1,985,000 after acquiring an additional 283,802 shares during the period. Acadian Asset Management LLC boosted its position in Idera Pharmaceuticals by 273.5% during the 2nd quarter. Acadian Asset Management LLC now owns 165,044 shares of the biotechnology company’s stock worth $440,000 after acquiring an additional 120,861 shares during the period. Jane Street Group LLC purchased a new position in Idera Pharmaceuticals during the 2nd quarter valued at about $237,000. Finally, Paloma Partners Management Co purchased a new position in Idera Pharmaceuticals during the 2nd quarter valued at about $228,000. 32.69% of the stock is owned by hedge funds and other institutional investors.

Idera Pharmaceuticals Company Profile

Idera Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for oncology in the United States. It offers Tilsotolimod, a synthetic phosphorothioate oligonucleotide that acts as a direct agonist of TLR9 to stimulate the immune systems and for treating solid tumors, metastatic melanoma, squamous cell carcinoma, and colorectal cancer.

Featured Story: What is range trading?

Get a free copy of the Zacks research report on Idera Pharmaceuticals (IDRA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Idera Pharmaceuticals (NASDAQ:IDRA)

Receive News & Ratings for Idera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Idera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.